The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Inclusion Criteria:

* Written informed consent provided
* Males or females aged ≥18 years
* Able to comply with the required protocol and follow-up procedures、
* Pathologically diagnosed of potentially resectable non-small cell lung cancer with stage II-IIIA (TNM 8th edition)
* Measurable disease must be characterized according to RECIST 1.1 criteria
* ECOG performance status 0-1
* Regardless of PD-L1 expression
* EGFR mutation (-) and ALK translocation (-)
* Pulmonary function could be well tolerated by lobectomy or pneumonectomy

Exclusion Criteria:

* EGFR mutation (+) or ALK translocation (+)
* Active Central nervous system (CNS) metastases
* Patients with active, known or suspected autoimmune disease.
* Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included
* Patients with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment
* Inhaled or topical steroids, and adrenal replacement steroid doses \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
* Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and/or poor lung function. Patients with other active malignancy requiring concurrent intervention and/ or concurrent treatment with other investigational drugs or anti-cancer therapy
* Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/ dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
* Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
* Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways Patients with positive test for hepatitis B virus surface antigen (HBVsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating active hepatitis
* Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Patients with history of allergy to study drug components excipients
* Women who are pregnant or in the period of breastfeeding
* Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study
* In case of doubt please contact trial team.